ATAI
NASDAQ · Pharmaceuticals
Ataibeckley Inc
$4.03
+0.02 (+0.50%)
Financial Highlights (FY 2026)
Revenue
6.66M
Net Income
-1,071,758,508
Gross Margin
—
Profit Margin
-16,142.0%
Rev Growth
+161.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 50.7% | 50.7% |
| Operating Margin | -15,582.3% | -28,039.7% | 19.6% | 21.3% |
| Profit Margin | -16,142.0% | -46,040.8% | 14.9% | 14.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 6.66M | 2.70M | 436.73M | 411.33M |
| Gross Profit | — | — | 221.31M | 208.44M |
| Operating Income | -1,037,436,216 | -757,020,072 | 85.54M | 87.55M |
| Net Income | -1,071,758,508 | -1,191,899,115 | 64.85M | 60.17M |
| Gross Margin | — | — | 50.7% | 50.7% |
| Operating Margin | -15,582.3% | -28,039.7% | 19.6% | 21.3% |
| Profit Margin | -16,142.0% | -46,040.8% | 14.9% | 14.6% |
| Rev Growth | +161.0% | -75.3% | -6.2% | +4.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 116.59M | 135.87M | 139.90M |
| Total Equity | — | 577.15M | 567.13M | 542.89M |
| D/E Ratio | — | 0.20 | 0.24 | 0.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,079,556,593 | -1,216,403,523 | 102.81M | 96.57M |
| Free Cash Flow | — | — | 81.44M | 75.18M |